Zymeworks has entered into a definitive agreement to acquire Theravance Biopharma (TBPH) in a transaction valued at approximately $929 million, structured as a combination of cash and contingent value rights (CVRs). CVRs introduce additional upside tied to future milestones — likely regulatory or commercial events — beyond the base cash consideration. Theravance posted revenue of $107.5M for FY2025, a notable 66.9% year-over-year increase, with an unusually high net margin of 98.5% and diluted EPS of $2.06, suggesting the underlying business had reached a lean, royalty-like cash-flow profile that made it an attractive acquisition target.

The deal is significant for both companies: TBPH shareholders receive deal certainty at what appears to be a premium to where the stock had been trading, while Zymeworks gains Theravance's assets — likely including its royalty streams and any remaining pipeline candidates. The CVR component means the total payout to TBPH holders is contingent, so the effective value depends on milestone probability assumptions.

For traders, TBPH now becomes a pure merger-arb play. The key tension is how wide the spread is between current TBPH price and the deal's cash component, and how much optionality the CVR carries. Deals of this structure can trade at a discount to the headline number if the CVR is viewed as speculative or if closing risk (regulatory, financing) is elevated.

What to watch: the deal's expected closing timeline, any regulatory hurdles (FTC/antitrust review given biotech M&A scrutiny), and how the market prices the CVR milestones. If the spread narrows quickly, arb opportunity diminishes; if it stays wide, it implies the market sees closing risk or discounts the CVR heavily.